Clinical Trial

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Study acronym: BRIO
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-31; most recent amendment 2024-11-14.
Status change: Not Yet Recruiting → Recruiting 2024-11-14
Trial Details
NCT Number NCT05979818
Lead Sponsor Second Xiangya Hospital of Central South University
Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions Non Small Cell Lung Cancer, Propranolol
Enrollment 6 participants
Start Date 2024-11-13
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-19